Alcon

Title: Methods and Compositions for Increasing RNA Interference
Patent Number: 8,865,668
Filed: Feb. 20, 2009

Title: Methods and Compositions Involving microRNA
Patent Number: 8,568,971
Filed: Sept. 24, 2010
Lead Inventor: David Brown, Asuragen

Title: Compositions and Methods for Inhibiting Expression of a Target Gene
Patent Number: 8,546,143
Filed: Sept. 29, 2010
Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals

Title: Compositions and Methods for siRNA Inhibition of Angiogenesis
Patent Number: 8,541,384
Filed: June 8, 2006
Lead Inventor: Michael Tolentino, University of Pennsylvania

Title: Methods for Detection and Quantitation of Small RNAs
Patent Number: 8,399,221
Filed: Nov. 4, 2008
Lead Inventor: Daniel Kim, SA Biosciences

Title: Compositions and Methods for Inhibiting Expression of Factor VII Gene
Patent Number: 8,334,273
Filed: Dec. 19, 2010

Title: iRNA Agents Targeting VEGF
Patent Number: 8,293,719
Filed: March 8, 2011
Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

Title: Method and Substances for Isolating miRNAs
Patent Number: 8,278,035
Filed: Aug. 18, 2006
Lead Inventor: Elliott Dawson, Bioventures

Title: Lipophilic Nucleic Acid Delivery Vehicle and Methods of Use Thereof
Patent Number: 8,268,796
Filed: June 26, 2009

Title: Compositions and Methods for Topical Delivery of Oligonucleotides
Patent Number: 8,168,600
Filed: April 21, 2005
Lead Inventor: Sujatha Dokka, Isis Pharmaceuticals

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.